The 36-month beta value for TXG is also noteworthy at 1.98. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 2 rating it as “overweight,” 9 rating it as “hold,” and 0 rating it as “sell.”
The public float for TXG is 103.39M, and at present, short sellers hold a 15.49% of that float. The average trading volume of TXG on June 17, 2025 was 3.72M shares.
TXG) stock’s latest price update
The stock price of 10x Genomics Inc (NASDAQ: TXG) has jumped by 5.71 compared to previous close of 10.41. Despite this, the company has seen a gain of 9.12% in its stock price over the last five trading days. newsfilecorp.com reported 2025-06-12 that Report shines a spotlight on continued leadership in responsible mining (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario–(Newsfile Corp. – June 12, 2025) – Torex Gold Resources Inc. (the “Company” or “Torex”) (TSX: TXG) today released its 2024 Responsible Gold Mining Report (the “Report”) titled Building from Strength, the Company’s tenth annual disclosure of its safety, environmental, social and governance performance. The Report can be found on the Company’s website at www.torexgold.com.
TXG’s Market Performance
TXG’s stock has risen by 9.12% in the past week, with a monthly rise of 19.67% and a quarterly rise of 2.32%. The volatility ratio for the week is 3.44% while the volatility levels for the last 30 days are 4.21% for 10x Genomics Inc The simple moving average for the last 20 days is 16.32% for TXG’s stock, with a simple moving average of -19.80% for the last 200 days.
Analysts’ Opinion of TXG
Many brokerage firms have already submitted their reports for TXG stocks, with Leerink Partners repeating the rating for TXG by listing it as a “Market Perform.” The predicted price for TXG in the upcoming period, according to Leerink Partners is $12 based on the research report published on February 13, 2025 of the current year 2025.
Leerink Partners, on the other hand, stated in their research note that they expect to see TXG reach a price target of $35. The rating they have provided for TXG stocks is “Outperform” according to the report published on September 03rd, 2024.
Jefferies gave a rating of “Buy” to TXG, setting the target price at $24 in the report published on July 22nd of the previous year.
TXG Trading at 25.38% from the 50-Day Moving Average
After a stumble in the market that brought TXG to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -55.53% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TXG starting from Saxonov Serge, who sale 9,343 shares at the price of $8.30 back on May 22 ’25. After this action, Saxonov Serge now owns 1,083,625 shares of 10x Genomics Inc, valued at $77,540 using the latest closing price.
Hindson Benjamin J., the of 10x Genomics Inc, sale 7,485 shares at $8.30 during a trade that took place back on May 22 ’25, which means that Hindson Benjamin J. is holding 448,374 shares at $62,120 based on the most recent closing price.
Stock Fundamentals for TXG
Current profitability levels for the company are sitting at:
- -0.28 for the present operating margin
- 0.69 for the gross margin
The net margin for 10x Genomics Inc stands at -0.25. The total capital return value is set at -0.22. Equity return is now at value -22.03, with -17.20 for asset returns.
Based on 10x Genomics Inc (TXG), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at 0.71. The debt to equity ratio resting at 0.11. The interest coverage ratio of the stock is -57463.0.
Currently, EBITDA for the company is -133.99 million with net debt to EBITDA at 2.34. When we switch over and look at the enterprise to sales, we see a ratio of 1.73. The receivables turnover for the company is 11.89for trailing twelve months and the total asset turnover is 0.69. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.37.
Conclusion
In summary, 10x Genomics Inc (TXG) has had a mixed performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
